See more : Megaport Limited (MGPPF) Income Statement Analysis – Financial Results
Complete financial analysis of Orthofix Medical Inc. (OFIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orthofix Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- King’s Metal Fiber Technologies Co., Ltd. (6832.TWO) Income Statement Analysis – Financial Results
- Curative Biosciences, Inc. (CBDX) Income Statement Analysis – Financial Results
- Poppins Corporation (7358.T) Income Statement Analysis – Financial Results
- Pacific Millennium Packaging Group Corporation (1820.HK) Income Statement Analysis – Financial Results
- Titan Kogyo, Ltd. (4098.T) Income Statement Analysis – Financial Results
Orthofix Medical Inc. (OFIX)
About Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 746.64M | 460.71M | 464.48M | 406.56M | 459.96M | 453.04M | 433.82M | 409.79M | 396.49M | 402.28M | 400.53M | 462.32M | 578.99M | 564.37M | 545.64M | 519.68M | 490.32M | 365.36M | 313.30M | 286.64M | 203.71M | 177.60M | 162.36M | 131.78M | 121.28M | 104.10M | 90.00M | 77.20M | 52.30M | 39.60M | 31.40M | 28.00M | 20.90M |
| Cost of Revenue | 260.37M | 123.54M | 114.91M | 101.89M | 100.61M | 96.63M | 93.04M | 87.85M | 86.53M | 98.91M | 102.30M | 86.49M | 139.19M | 131.72M | 138.45M | 152.01M | 129.03M | 93.63M | 83.79M | 79.18M | 51.09M | 44.82M | 42.95M | 28.41M | 30.19M | 26.50M | 22.70M | 21.10M | 18.00M | 12.70M | 8.90M | 8.00M | 0.00 |
| Gross Profit | 486.27M | 337.17M | 349.57M | 304.67M | 359.35M | 356.41M | 340.79M | 321.94M | 309.96M | 303.37M | 298.23M | 375.83M | 439.80M | 432.65M | 407.19M | 367.66M | 361.29M | 271.73M | 229.52M | 207.46M | 152.62M | 132.78M | 119.41M | 103.37M | 91.10M | 77.60M | 67.30M | 56.10M | 34.30M | 26.90M | 22.50M | 20.00M | 20.90M |
| Gross Profit Ratio | 65.13% | 73.18% | 75.26% | 74.94% | 78.13% | 78.67% | 78.55% | 78.56% | 78.18% | 75.41% | 74.46% | 81.29% | 75.96% | 76.66% | 74.63% | 70.75% | 73.68% | 74.37% | 73.26% | 72.38% | 74.92% | 74.76% | 73.55% | 78.44% | 75.11% | 74.54% | 74.78% | 72.67% | 65.58% | 67.93% | 71.66% | 71.43% | 100.00% |
| Research & Development | 80.23M | 49.07M | 49.62M | 39.06M | 34.64M | 33.22M | 29.70M | 28.80M | 26.39M | 24.99M | 26.77M | 28.58M | 25.15M | 30.35M | 31.46M | 30.84M | 24.22M | 54.99M | 11.32M | 11.47M | 8.13M | 7.51M | 6.99M | 6.89M | 6.40M | 5.90M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 144.66M | 79.97M | 69.35M | 67.95M | 85.61M | 84.51M | 74.39M | 74.40M | 87.16M | 76.79M | 65.15M | 53.83M | 86.47M | 88.63M | 88.87M | 288.72M | 259.89M | 199.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 385.74M | 228.81M | 221.32M | 204.43M | 223.68M | 205.53M | 198.37M | 181.29M | 178.08M | 166.55M | 176.58M | 200.34M | 233.61M | 230.94M | 215.94M | 40.00K | 38.00K | 40.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 530.40M | 308.78M | 290.67M | 272.38M | 309.28M | 290.03M | 272.76M | 255.69M | 265.24M | 243.34M | 241.73M | 254.17M | 320.08M | 319.57M | 304.81M | 288.72M | 259.89M | 199.02M | 151.92M | 133.07M | 97.22M | 81.63M | 77.78M | 62.35M | 54.65M | 49.90M | 44.90M | 43.30M | 24.60M | 14.20M | 11.20M | 10.90M | 0.00 |
| Other Expenses | 14.76M | -3.15M | -3.34M | 8.38M | -8.14M | -6.38M | -4.00M | -17.18M | -259.00K | -2.90M | 490.00K | -3.68M | 5.60M | -6.26M | 7.04M | 305.05M | 18.16M | 8.87M | 6.57M | 7.92M | 6.68M | 703.00K | 4.14M | 4.03M | 6.83M | 6.50M | 6.50M | 6.20M | 2.20M | 1.10M | 700.00K | 800.00K | 0.00 |
| Operating Expenses | 625.38M | 357.84M | 340.29M | 311.44M | 343.92M | 323.25M | 302.46M | 284.49M | 291.63M | 270.62M | 271.18M | 284.85M | 350.82M | 343.66M | 343.31M | 624.61M | 302.26M | 262.88M | 169.81M | 152.46M | 112.03M | 89.84M | 88.91M | 73.27M | 67.88M | 62.30M | 56.20M | 49.50M | 26.80M | 15.30M | 11.90M | 11.70M | 0.00 |
| Cost & Expenses | 885.75M | 481.39M | 455.21M | 413.33M | 444.53M | 419.88M | 395.50M | 372.35M | 378.15M | 369.53M | 373.48M | 371.34M | 490.01M | 475.38M | 481.76M | 776.62M | 431.29M | 356.51M | 253.60M | 231.64M | 163.12M | 134.66M | 131.86M | 101.68M | 98.07M | 88.80M | 78.90M | 70.60M | 44.80M | 28.00M | 20.80M | 19.70M | 0.00 |
| Interest Income | 0.00 | 1.29M | 1.84M | 2.48M | 122.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 330.00K | 193.00K | 542.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.63M | 1.29M | 1.84M | 2.48M | 122.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 0.00 | 9.46M | 17.23M | 24.63M | 20.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 60.60M | 29.02M | 29.60M | 30.55M | 24.70M | 18.66M | 20.12M | 20.84M | 20.92M | 2.28M | 22.66M | 20.26M | 22.78M | 22.52M | 22.34M | 32.68M | 32.33M | 16.96M | 17.53M | 15.08M | 6.95M | 5.83M | 7.95M | 7.38M | 6.83M | 6.50M | 6.50M | 6.20M | 2.20M | 1.10M | 700.00K | 800.00K | 0.00 |
| EBITDA | -79.45M | 12.60M | 17.94M | 32.66M | -2.23M | 41.54M | 60.94M | 39.87M | 29.92M | 40.64M | 14.05M | 96.19M | 53.27M | 112.15M | 87.19M | -243.53M | 70.39M | 25.81M | 116.76M | 70.08M | 47.53M | 48.77M | 38.45M | 41.51M | 30.05M | 21.77M | 17.56M | 12.80M | 9.70M | 12.70M | 11.30M | 9.10M | 20.90M |
| EBITDA Ratio | -10.64% | -5.17% | 5.78% | 8.83% | 10.79% | 8.00% | 8.26% | 9.63% | 6.92% | 12.59% | 20.43% | 24.06% | 19.30% | 19.70% | 15.60% | 15.80% | 22.83% | 6.07% | 11.48% | 24.53% | 26.67% | 28.93% | 23.91% | 2.39% | 24.76% | 16.52% | 20.67% | 18.78% | 62.72% | 29.29% | 35.03% | 31.43% | 100.00% |
| Operating Income | -139.11M | -20.67M | -6.23M | 1.62M | 24.94M | 30.09M | 40.81M | 21.07M | 9.26M | 17.14M | -5.09M | 89.01M | 32.52M | 88.99M | 63.88M | -256.95M | 38.06M | 8.85M | 59.71M | 55.00M | 40.58M | 42.94M | 30.50M | 22.73M | 23.22M | 15.30M | 11.10M | 6.60M | 7.50M | 11.60M | 10.60M | 8.30M | 20.90M |
| Operating Income Ratio | -18.63% | -4.49% | -1.34% | 0.40% | 5.42% | 6.64% | 9.41% | 5.14% | 2.33% | 4.26% | -1.27% | 19.25% | 5.62% | 15.77% | 11.71% | -49.44% | 7.76% | 2.42% | 19.06% | 19.19% | 19.92% | 24.18% | 18.78% | 17.24% | 19.14% | 14.70% | 12.33% | 8.55% | 14.34% | 29.29% | 33.76% | 29.64% | 100.00% |
| Total Other Income/Expenses | -9.57M | -4.44M | -5.18M | -366.50K | -8.27M | -7.21M | -4.42M | -2.04M | -748.00K | -4.68M | 589.00K | -7.10M | -33.88M | -10.96M | -23.85M | -38.09M | -23.32M | -2.53M | 35.81M | -4.64M | -1.27M | -2.41M | -1.67M | 38.33M | -2.39M | 1.70M | -3.86M | -4.30M | -24.70M | 300.00K | -300.00K | -800.00K | -20.90M |
| Income Before Tax | -148.68M | -17.71M | -13.50M | -368.00K | -27.05M | 22.89M | 36.39M | 19.02M | 8.51M | 12.46M | -6.52M | 82.73M | 20.70M | 72.40M | 40.02M | -295.04M | 14.80M | 6.32M | 95.52M | 50.36M | 39.32M | 40.53M | 28.83M | 61.05M | 20.83M | 17.00M | 7.20M | 2.30M | -17.20M | 11.90M | 10.30M | 7.50M | 0.00 |
| Income Before Tax Ratio | -19.91% | -3.84% | -2.91% | -0.09% | -5.88% | 5.05% | 8.39% | 4.64% | 2.15% | 3.10% | -1.63% | 17.89% | 3.58% | 12.83% | 7.33% | -56.77% | 3.02% | 1.73% | 30.49% | 17.57% | 19.30% | 22.82% | 17.76% | 46.33% | 17.17% | 16.33% | 8.00% | 2.98% | -32.89% | 30.05% | 32.80% | 26.79% | 0.00% |
| Income Tax Expense | 2.72M | 2.04M | 24.88M | -2.89M | 1.41M | 9.07M | 29.10M | 15.53M | 10.85M | 16.20M | 9.16M | 28.79M | 21.78M | 28.19M | 15.55M | -66.48M | 3.77M | 13.36M | 22.11M | 16.21M | 14.59M | 12.88M | 7.87M | 16.23M | 7.91M | 2.70M | 4.10M | 2.80M | 2.60M | 2.80M | 2.60M | 1.30M | -5.00M |
| Net Income | -151.40M | -19.75M | -38.38M | 2.52M | -28.46M | 13.81M | 6.22M | 3.06M | -2.81M | -8.54M | -28.48M | 51.30M | -1.07M | 44.21M | 24.47M | -228.55M | 10.97M | -7.04M | 73.40M | 34.15M | 24.73M | 25.91M | 20.96M | 44.82M | 12.91M | 14.30M | 3.10M | -500.00K | -19.80M | 9.10M | 7.70M | 6.20M | 5.00M |
| Net Income Ratio | -20.28% | -4.29% | -8.26% | 0.62% | -6.19% | 3.05% | 1.43% | 0.75% | -0.71% | -2.12% | -7.11% | 11.10% | -0.19% | 7.83% | 4.49% | -43.98% | 2.24% | -1.93% | 23.43% | 11.91% | 12.14% | 14.59% | 12.91% | 34.01% | 10.65% | 13.74% | 3.44% | -0.65% | -37.86% | 22.98% | 24.52% | 22.14% | 23.92% |
| EPS | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.75 | 0.34 | 0.17 | -0.15 | -0.46 | -1.52 | 2.70 | -0.06 | 2.51 | 1.43 | -13.37 | 0.66 | -0.44 | 4.61 | 2.22 | 1.76 | 1.96 | 1.60 | 3.40 | 0.99 | 1.10 | 0.24 | -0.04 | -1.78 | 0.84 | 0.71 | 0.61 | 0.57 |
| EPS Diluted | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.73 | 0.34 | 0.17 | -0.15 | -0.46 | -1.52 | 2.64 | -0.06 | 2.47 | 1.42 | -13.37 | 0.64 | -0.44 | 4.51 | 2.14 | 1.68 | 1.76 | 1.42 | 3.20 | 0.97 | 1.07 | 0.23 | -0.04 | -1.78 | 0.84 | 0.71 | 0.61 | 0.57 |
| Weighted Avg Shares Out | 36.73M | 20.05M | 19.69M | 19.27M | 18.90M | 18.49M | 18.12M | 18.14M | 18.80M | 18.46M | 18.70M | 18.98M | 18.22M | 17.60M | 17.12M | 17.10M | 16.64M | 16.17M | 15.91M | 15.40M | 14.06M | 13.20M | 13.09M | 13.18M | 13.03M | 12.97M | 12.92M | 12.50M | 11.12M | 10.83M | 10.85M | 10.16M | 8.77M |
| Weighted Avg Shares Out (Dil) | 36.73M | 20.05M | 19.69M | 19.39M | 18.90M | 18.91M | 18.50M | 18.46M | 18.80M | 18.46M | 18.70M | 19.39M | 18.22M | 17.91M | 17.20M | 17.10M | 17.05M | 16.17M | 16.29M | 15.97M | 14.68M | 14.69M | 14.74M | 13.99M | 13.36M | 13.29M | 13.48M | 12.50M | 11.12M | 10.83M | 10.85M | 10.16M | 8.77M |
Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX). Investors who purchased Orthofix securities prior to October...
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in...
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call...
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ:...
FINAL REMINDER OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Orthofix Medical Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX)...
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action
SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of former SeaSpine Holdings Corporation shareholders that purchased or otherwise acquired newly issued Orthofix Medical Inc. (NASDAQ: OFIX) stock in...
Orthofix (OFIX) Q3 Earnings Surpass Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to earnings of $0.07 per share a year ago.
Orthofix Announces New Term Loan
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period....
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third...
FINAL OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Orthofix Medical Inc. Investors to Join the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX)...
Source: https://incomestatements.info
Category: Stock Reports